Navigation Links
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Date:5/29/2012

ults from the ENCORE clinical program provide the basis for moving entinostat into pivotal, phase 3 testing in metastatic breast complemented by biomarker driven confirmatory studies in lung cancer.

About Syndax

Syndax is a late-stage oncology company initiating pivotal programs in solid tumors based on employing epigenetic strategies to overcome the problem of resistance in oncology care. Syndax holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor being developed in advanced breast and lung cancer. Randomized, placebo-controlled phase 2 studies with entinostat have demonstrated promising results in combination with aromatase inhibitors in breast cancer (ENCORE 301) and with the EGFR-TKI erlotinib (ENCORE 401) in non-small cell lung cancer providing the basis for moving entinostat into pivotal, phase 3 testing across a platform of solid tumor indications. NCI and Syndax are collaborating on the development of entinostat under a Cooperative Research and Development Agreement.

The company is supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. Formed in 2005, Syndax's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. For more information please visit www.syndax.com.

Syndax Contact Information
E. Blair Schoeb
Phone: 908.277.0386
Email: bschoeb@syndax.com


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... VIEW, Calif. , July 22, 2014 /PRNewswire/ ... resonance imaging (MRI) market, Frost & Sullivan recognizes ... for Product Leadership. Siemens Healthcare,s FREEZEit solution, which ... the need for robust and motion-insensitive imaging. The ... boosted the evolution of body MRI imaging in ...
(Date:7/22/2014)... Ariz. , July 22, 2014  A ... of a SynCardia temporary Total Artificial ... Rochester,s Strong Memorial Hospital with the Freedom® portable ... Fontana, a 64-year-old retiree from a ... decades. He managed the condition with medications, an ...
(Date:7/22/2014)... 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), a ... and healthcare products, announced today that the company ... "We are pleased to sponsor Operation ... and Chairman of PuraMed BioScience. "Research shows that ... experience migraines much more frequently than the general ...
Breaking Medicine Technology:Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3
... trial -SOUTH SAN FRANCISCO, Calif., March 30 Hyperion ... II study of HPN-100 for the treatment of urea ... 27th at the 16th Annual Clinical Genetics Meeting of ... M.D., Ph.D., Howard Hughes Medical Institute Investigator and Professor ...
... studied in combination with the most commonly used doses ... in patients with mixed dyslipidemiaORLANDO, Fla., March 29 ... ,s TRILIPIX(R) (fenofibric acid) delayed-release capsules in combination with ... TRILIPIX 135 mg in combination with rosuvastatin calcium ...
Cached Medicine Technology:Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 2Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 3Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5
(Date:7/22/2014)... 22, 2014 CyraCom has been ranked ... in the translation and interpreting industry. Released June 2014 ... report titled "The Language Services Market: 2014," also ranked ... world, moving up two spots from 2013. , In ... LSPs that provide interpretation services – a subset of ...
(Date:7/22/2014)... The Muscular Dystrophy Association (MDA) and Jiffy Lube today ... campaign that will raise funds to help save and ... muscle disease. , As part of the campaign, ... centers through Sept. 1, 2014 to make a donation to ... the fight for muscle health. Since 2012, Jiffy Lube has ...
(Date:7/22/2014)... Paul, Minn. (PRWEB) July 22, 2014 ... dental comfort technology, the Restful Jaw ®. The ... the patient’s jaw while minimizing jaw pain, fatigue and ... can experience shorter treatment times when patients do not ... pain. , The Restful Jaw is a vital ...
(Date:7/22/2014)... HealthDay Reporter MONDAY, July 21, 2014 (HealthDay ... asthma appears to offer relief to people with chronic hives ... The prescription drug -- omalizumab (Xolair) -- is already ... approval earlier this year for that use. The current ... dose for a six-month period it seems to be both ...
(Date:7/22/2014)... at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute ... one of the most complex and difficult-to-treat forms ... , Locally advanced pancreatic cancer has the lowest ... cumulative five-year survival rate of only 4 percent ... an option for patients because tumors often involve ...
Breaking Medicine News(10 mins):Health News:CyraCom Ranked Among the World’s Largest Language Service Providers 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 2Health News:Jiffy Lube® Supports Fight Against Muscle Disease with Third Annual MUSCLE UP® Campaign 3Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 2Health News:Introducing the Restful Jaw – The Only Device Designed to Protect the Patient’s Jaw 3Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 2Health News:Unique study focuses on combined treatment approach for locally advanced pancreatic cancer 3
... Health Plans Offer Broader ChoiceEAGAN, Minn., April 13 ... today announced the largest array of individual health plan ... buy health insurance on their own. The new plans ... series of "design your own health plan" sessions, in ...
... 13 The American Heart Association, with support from ... three research centers to study the development and mechanisms ... next four year, the centers will be conducting studies ... help improve outcomes for heart attack and heart failure ...
... 5,000 years ago , , MONDAY, April 13 (HealthDay News) -- ... stomach,s sake," may have been heeded more than 5,000 years ... residues found in wine jars left in the tomb of ... had been steeped in herbs including balm, coriander, mint and ...
... Jean Nordin Evans, DDS, FIND and Dr. Robert Evans, DMD, FIND, FAGD ... new medical center located at Mill Run Plaza. , ... Groton, MA ... visionary, announced today that Groton Wellness Medical Center has opened its doors ...
... beyond mere placebo effect , , MONDAY, April 13 (HealthDay ... a 25 percent less nausea during radiation treatments, a new ... Journal of Pain and Symptom Management , also discounted ... as a placebo than an actual pain reliever. , ...
... 13 The Advertising Council, in partnership,with Autism Speaks, ... public,service advertisements (PSAs) featuring professional golfer Ernie Els, and ... about autism and to urge,parents to learn the early ... in every 150 children. , , ...
Cached Medicine News:Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 2Health News:Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota 3Health News:Three Medical Centers Awarded Funds to Study Generation of Cardiac Muscle Cells 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 2Health News:Pharoah's Wine Jar Yields Medicinal Secrets 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 2Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 3Health News:Top Medical and Dental Team Opens Groton Wellness Medical Center in Groton, MA 4Health News:Wristbands May Lessen Nausea After Radiation 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano angled tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson angled tying forceps is long with tying platform 10 mm, serrated handle and polished finish....
Medicine Products: